Hematopoiesis News Volume 6.33 | Aug 25 2015

    0
    28

    Hematopoiesis News 6.33 August 25, 2015

    Hematopoiesis News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  HN on Twitter

     
    TOP STORY
    Emergency Program Ensures Blood Coagulation
    Scientists have now discovered an emergency program in mice that bypasses the known pathway of blood stem cell differentiation so that the vital thrombocytes are rapidly replenished. They discovered, within the hematopoietic stem cells, a small cell population that is defined molecularly to induce differentiation of megakaryocytes, the progenitors of platelets. [Press release from DKFZ discussing online prepublication in Cell Stem Cell] Press Release | Abstract | Graphical Abstract
    Learn more about T cell activation and expansion with ImmunoCultâ„¢

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    Kindlin-3-Mediated Integrin Adhesion Is Dispensable for Quiescent but Essential for Activated Hematopoietic Stem Cells
    Scientists report that Kindlin-3-mediated integrin activation controls homing of hematopoietic stem cells (HSCs) to the bone marrow (BM) and the retention of activated HSCs and hematopoietic progenitor cells but not of quiescent HSCs in their BM niches. [J Exp Med] Abstract

    Dipeptide Species Regulate p38MAPK-Smad3 Signaling to Maintain Chronic Myelogenous Leukemia Stem Cells
    The authors surveyed global metabolic differences between murine normal hematopoietic stem cells (HSCs) and chronic myelogenous leukemia (CML) stem cells using metabolomics techniques. They showed that CML stem cells accumulate significantly higher levels of certain dipeptide species than normal HSCs. [Nat Commun] Full Article

    FOXF1 Inhibits Hematopoietic Lineage Commitment during Early Mesoderm Specification
    Researchers revealed that FOXF1-expressing mesoderm was derived from FLK1+ progenitors and that in vitro this transcription factor was expressed in smooth muscle and transiently in endothelial lineages but not in hematopoietic cells. [Development] Abstract

    Targeting BTK for the Treatment of FLT3-ITD Mutated Acute Myeloid Leukemia
    Researchers placed the FMS-like-tyrosine-kinase-3 (FLT3)-ITD upstream of Bruton’s tyrosine kinase (BTK) in acute myeloid leukemia (AML) and showed that the BTK inhibitor ibrutinib inhibited the survival and proliferation of FLT3-ITD primary AML blasts and AML cell lines. [Sci Rep] Full Article

    Salarin C Inhibits Maintenance of Hypoxia-Selected Chronic Myeloid Leukemia Progenitor Cells
    Salarin C, an anticancer macrolide extracted from the Fascaplysinopsis sponge, was tested for its activity on chronic myeloid leukemia cells, especially after their incubation in atmosphere at 0.1% oxygen. Salarin C induced mitotic cycle arrest, apoptosis and DNA damage. [Cell Cycle] Abstract

    Olive Leaf Components Apigenin 7-Glucoside and Luteolin 7-Glucoside Direct Human Hematopoietic Stem Cell Differentiation towards Erythroid Lineage
    Main olive leaf phytochemicals oleuropein, apigenin 7-glucoside and luteolin 7-glucoside were investigated for their potential effects on hematopoietic stem cell differentiation using both phenotypic and molecular analysis. [Differentiation] Abstract

    Loss of the Homeodomain Transcription Factor Prep1 Perturbs Adult Hematopoiesis in the Bone Marrow
    Scientists generated hematopoietic- and endothelial cell-specific Prep1-deficient mice and demonstrated that expression of Prep1 in the hematopoietic cell compartment is not essential for either embryonic or adult hematopoiesis, although its absence caused significant hematopoietic abnormalities in the adult bone marrow. [PLoS One] Full Article

    CLINICAL RESEARCH

    Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Hematopoietic Cell Transplantation
    In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). Investigators compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. [Bone Marrow Transplant] Abstract

    Numerical Impairment of Nestin+ Bone Marrow Niches in Acute GvHD after Allogeneic Hematopoietic Stem Cell Transplantation for AML
    To investigate whether acute GvHD reduces the number of nestin+ perivascular bone marrow stem cell niches, researchers examined patients with AML who had undergone allogeneic hematopoietic stem cell transplantation. [Bone Marrow Transplant] Abstract

    Learn more about our standardized tools for cord blood banking

     
    REVIEWS
    Autologous Stem Cell Transplantation for Adult Acute Leukemia in 2015: Time to Rethink? Present Status and Future Prospects
    The use of autologous stem cell transplantation as consolidation therapy for adult patients with acute leukemia has declined over time. However, multiple randomized studies in the past have reported lower relapse rates after autologous transplantation compared with chemotherapy and lower non-relapse mortality rates compared with allogeneic transplantation. [Bone Marrow Transplant] Abstract

    Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

    IBC’s Cell Therapy Bioprocessing & Commercialization meeting

     
    INDUSTRY NEWS
    $52 Million NIH Grant Advances Clinical and Translational Research at UC San Diego
    The Clinical and Translational Research Institute at University of California, San Diego has received a five-year Clinical and Translational Science Award for approximately $52 million from the National Center for Advancing Translational Science, part of the National Institutes of Health (NIH). [UC San Diego Health] Press Release

    NYBC Partners with UC Davis Health System to Produce More Viable Stem Cell Therapies
    New York Blood Center (NYBC) announced a new collaboration with the University of California, Davis, Health System to manufacture specialized lines of stem cells as potential therapies for repair and regeneration of retina, kidney, lung and liver tissue, as well as for the treatment of neurodegenerative disorders such as Parkinson’s, Alzheimer’s and Huntington’s disease. [New York Blood Center] Press Release

    From our sponsor:
    Quickly find the whole-blood frequencies of human and mouse immune cell types.
    Download the app.

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW War on Cancer 2015
    October 20, 2015
    London, United Kingdom

    Visit our events page to see a complete list of events in the hematopoiesis community.

     
    JOB OPPORTUNITIES
    NEW Postdoctoral Fellow – HMGA Chromatin Remodeling Proteins in Cancer and Stem Cell Biology (Johns Hopkins University School of Medicine)

    Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

    Research Associate – Cell Separation (STEMCELL Technologies Inc.)

    Regulatory Coordinator – Leukemia (Fred Hutchinson Cancer Research Center)

    Postdoctoral Position – Hematologic Malignancies (Northwestern University)

    Postdoctoral Research Associate – Pharmacogenomics (St. Jude Children’s Research Hospital)

    Postdoctoral Fellow – Hematopoiesis (University Hospital of Cologne)

    Postdoctoral Fellow – Hematopoietic Regeneration and Myeloid Malignancies (Weill-Cornell Medical College)

    Postdoctoral Position – Hematopoietic Stem and Progenitor Cell Assays (Weill Cornell Medical School)

    Research Associate – Cell Biology (Editas Medicine)

    Clinical Research Coordinator – Chronic Lymphocytic Leukemia (Fred Hutchinson Cancer Research Center)


    Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Hematopoiesis News: Archives | Events | Contact Us